Kymera Therapeutics Inc.
KYMRHeld by 14 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying14 funds opened new positions. Next phase2 readout (KT-621): Jun 2027. Short interest: 15.2% of float.
Held by 14 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying14 funds opened new positions. Next phase2 readout (KT-621): Jun 2027. Short interest: 15.2% of float.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.